Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $20.05 USD
Change Today +0.21 / 1.06%
Volume 649.1K
BRKR On Other Exchanges
As of 5:20 PM 06/2/15 All times are local (Market data is delayed by at least 15 minutes).

bruker corp (BRKR) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/19/14 - $24.93
52 Week Low
11/7/14 - $17.26
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BRUKER CORP (BRKR)

bruker corp (BRKR) Related Bloomberg News

View More Bloomberg News

bruker corp (BRKR) Related Businessweek News

No Related Businessweek News Found

bruker corp (BRKR) Details

Bruker Corporation, together with its subsidiaries, designs, manufactures, sells, and services proprietary life science and materials research systems, and associated products worldwide. It operates through two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. The company offers life science and materials research systems and associated products used in life science research, pharmaceuticals, applied markets, nanotechnology, cell biology, clinical research, microbiology, and in-vitro diagnostics. Its technology platforms include magnetic resonance technologies, mass spectrometry technologies, gas chromatography technologies, infrared and Raman molecular spectroscopy technologies, X-ray technologies, spark-optical emission spectroscopy, atomic force microscopy, fluorescence optical microscopy, and stylus and optical metrology technology. The company also sells a range of field analytical systems for chemical, biological, radiological, nuclear, and explosive detection; and develops and manufactures low temperature and high temperature superconducting wire products, as well as superconducting wire and superconducting devices for use in magnet technology, physics research, and energy applications. Bruker Corporation’s customer base includes life science, pharmaceutical, biotechnology and molecular diagnostic research companies, academic institutions, advanced materials, and semiconductor industries, as well as government agencies. The company markets its products through direct sales force; and distributors, independent sales representatives, and other representatives. Bruker Corporation was founded in 1991 and is headquartered in Billerica, Massachusetts.

6,100 Employees
Last Reported Date: 02/27/15
Founded in 1991

bruker corp (BRKR) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $598.7K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $509.5K
President of Bruker Daltonics Division and Pr...
Total Annual Compensation: $717.2K
President of Bruker MAT Group
Total Annual Compensation: $399.5K
President of Bruker BioSpin Group
Total Annual Compensation: $394.0K
Compensation as of Fiscal Year 2014.

bruker corp (BRKR) Key Developments

Bruker Introduces MALDI Tissuetyper™ Solution

Bruker Corporation announced the launch of the novel MALDI Tissuetypersolution, based on the newrapifleXMALDI-TOF Mass Spectrometry system. The introduction of the revolutionary rapifleX as the new instrument platform for MALDI imaging anatomical pathology research further enhances Bruker’s leadership position for MALDI-TOF-based applications solutions. The new rapifleX system eliminates many previous bottlenecks in mass spectrometry imaging (MSI), with much improved speed, throughput, ease-of-use, robustness and spatial resolution. At the same time, MSI maintenance efforts are reduced to a minimum by a streamlined design of the ion source for maximum uptime and optimized accessibility. The new MALDI Tissuetyper solution based on the rapifleX instrument redefines the key performance measures for MALDI imaging and allows for completely new projects and measurement strategies. The rapifleX system offers by far the high laser repetition rate on the market, combined with the best MALDI imaging spatial resolution. The instrument has a removable, self-aligning ion source for high customer service convenience. The MALDI Tissuetyper solution works up to 20 times faster than traditional MALDI-TOF systems, using Bruker’s break-through, proprietary smartbeam™ 3D laser. The new scanning smartbeam 3D laser provides a fast moving laser-beam which is synchronized with the movement of the MALDI target stage. In combination with the game-changing laser repetition rate of 10 kHz, this architecture allows for real high throughput where MALDI imaging researchers have dramatically increased flexibility in pixel size or target tissue size. Depending on the sample size, typical tissue sections can now be imaged in approximately 30 minutes. Mass spectrometry images from small tissue biopsies are available within a few minutes.

Bruker Announces MALDI PharmaPulse High-Throughput Screening (HTS) Solution for Drug Discovery

Bruker announced a new high-throughput screening (HTS) solution designed to help pharmaceutical companies achieve high throughput, lower cost and higher specificity in drug discovery. The new MALDI PharmaPulse solution combines the speed, sensitivity and ease-of-use of Bruker’s robust MALDI-TOF systems with HTS robotics and automation software from HighRes Biosolutions Inc. The new MALDI PharmaPulse solution is the latest addition to Bruker’s portfolio of innovative products designed to assist pharmaceutical, biotech and CRO customers accelerate drug discovery and development. Based on the autoflex speed MALDI TOF system, and incorporating an integrated automation solution from HighRes Biosolutions, this new HTS solution offers the fast commercially available mass spectrometry-based screening solution with significantly lower cost per sample. In addition, its label-free detection of substrates accelerates assay development, reduces complexity of screening, and potentially minimizes artifacts from interferences with the labels used in traditional HTS technologies. The unique capabilities of the novel MALDI PharmaPulse solution for driving higher throughput at dramatically lower costs for screening in drug discovery, include: Less than 1 second per sample analysis time, comparable to the pulse of the human heart, and fast enough for true high throughput screening (HTS). autoflex speed MALDI TOF equipped with proprietary 2 kHz smartbeam -II laser. Integrated automation solution from HighRes Biosolutions seamlessly prepares and feeds MALDI plates from 96, 384 or 1536 assay plates. MALDI-detection removes need for SPE cartridges or LC columns, uses 100x less solvent per sample than conventional LC-MS methods. Does not require derivatization in comparison to fluorescence workflows. Development times for new assays and complexity is dramatically reduced without the need for chromatographic method development, SPE or MRM setup, or derivatization protocols. The extremely low sample volumes required for detection enables “Single Well Kinetic Readout” by sampling multiple time points per assay. The full automation, coupled with speed of MALDI TOF, enables the screening of over 50.000 compounds per day. Due to this unique feature set, the MALDI PharmaPulseenables pharmaceutical customers to accelerate their drug discovery efforts with higher throughput assays, delivering higher quality results while lowering costs.

Bruker Introduces Comprehensive Mycobacteria Library 3.0 for High-Performance MALDI Biotyper Mycobacteria Identification

Bruker announced a major version 3.0 expansion of the proven Mycobacteria Libraryfor research use only on the MALDI Biotyper microbial mass spectrometry system. The new Mycobacteria Library 3.0 now includes 149 different species for comprehensive species coverage, enabling significantly improved rapid and accurate identification of almost all described mycobacteriaspecies. Intra-species diversity is covered by hundreds of analyzed strains. Twenty-four laboratories from nine countries from all over the world provided well-characterized clinical mycobacteria strains, completing an already comprehensive set of isolates from strain collections. A recently published research study has shown that out of 1,045 mycobacteria samples, 94% could be identified on the species level with high confidence, and another 4.5% could be identified with lower confidence [1], using Mycobacteria Library 3.0. The genus Mycobacterium includes, as major groups, the important pathogens of the Mycobacterium tuberculosis complex (MTC) and the non-tuberculous mycobacteria(NTM). Members of the latter group are increasingly the cause of opportunistic infections among immuno-compromised patients. This trend and the rise of antibiotic resistance in this genus require improved differentiation of mycobacteriaspecies. The identification of mycobacteria is one of the most challenging tasks of many microbiological research laboratories. For this purpose, Bruker has developed the optimized MycoEx™ preparation protocol, resulting in stream-lined and straightforward mycobacteria species identification, while ensuring the safety of technicians processing such samples. With the new MycoEx™ preparation protocol and the new Mycobacteria Library 3.0, the MALDI Biotyper has become an even more powerful research tool for the thorough characterization of mycobacteria.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BRKR:US $20.05 USD +0.21

BRKR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioMerieux €103.25 EUR -0.30
FEI Co $82.57 USD +0.57
National Instruments Corp $30.08 USD +0.23
Teledyne Technologies Inc $102.33 USD +0.41
Teradyne Inc $20.94 USD -0.27
View Industry Companies

Industry Analysis


Industry Average

Valuation BRKR Industry Range
Price/Earnings 61.7x
Price/Sales 1.9x
Price/Book 4.7x
Price/Cash Flow 61.5x
TEV/Sales 1.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BRUKER CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at